{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:09:14Z","timestamp":1773673754115,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,1,1]],"date-time":"2013-01-01T00:00:00Z","timestamp":1356998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2013,1]]},"DOI":"10.4158\/ep12325.or","type":"journal-article","created":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T21:03:25Z","timestamp":1358802205000},"page":"100-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["The Role of Bromocriptine-Qr in the Management of Type 2 Diabetes Expert Panel Recommendations"],"prefix":"10.1016","volume":"19","author":[{"given":"Alan J.","family":"Garber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Blonde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary T.","family":"Bloomgarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Dagogo-Jack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP12325.OR_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0735-1097(00)00732-4","article-title":"Management of coronary artery disease: therapeutic options in patients with diabetes","volume":"36","author":"Hammoud","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/EP12325.OR_bb0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2337\/diacare.21.1.69","article-title":"Impact of diabetes on mortality after the first myocardial infarction","volume":"21","author":"Miettinen","year":"1998","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12325.OR_bb0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1161\/hc5001.100528","article-title":"Impact of diabetes on the risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease","volume":"105","author":"Giri","year":"2002","journal-title":"Circulation"},{"key":"10.4158\/EP12325.OR_bb0030","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1464-5491.2008.02640.x","article-title":"Is diabetes a coronary risk equivalent? Systematic review and meta-analysis","volume":"26","author":"Bulugahapitiya","year":"2009","journal-title":"Diabetes Med"},{"key":"10.4158\/EP12325.OR_bb0035","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"10.4158\/EP12325.OR_bb0040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fendo.2012.00066","article-title":"Hypoglycemia in type 2 diabetes: current controversies and changing practices","volume":"3","author":"Bloomgarden","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.4158\/EP12325.OR_bb0045","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12325.OR_bb0050","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.2009.496","article-title":"Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction","volume":"301","author":"Kosiborod","year":"2009","journal-title":"JAMA"},{"key":"10.4158\/EP12325.OR_bb0055","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1056\/NEJMsa1103053","article-title":"Emergency hospitalizations for adverse drug events in older Americans","volume":"365","author":"Budnitz","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4158\/EP12325.OR_bb0060","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1477-7525-8-86","article-title":"Association of hypoglycemic symptoms with patients\u2019 rating of their health-related quality of life state: a cross sectional study","volume":"8","author":"Alvarez-Guisasola","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"10.4158\/EP12325.OR_bb0065","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/1756-0500-4-251","article-title":"Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: A survey study","volume":"4","author":"Marrett","year":"2011","journal-title":"BMC Res Notes"},{"key":"10.4158\/EP12325.OR_bb0070","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1172\/JCI116302","article-title":"Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus","volume":"91","author":"Dagogo-Jack","year":"1993","journal-title":"J Clin Invest"},{"key":"10.4158\/EP12325.OR_bb0075","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.amjmed.2011.08.008","article-title":"Death during intensive glycemic therapy of diabetes: mechanisms and implications","volume":"124","author":"Cryer","year":"2011","journal-title":"Am J Med"},{"key":"10.4158\/EP12325.OR_bb0080","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/14740330903081725","article-title":"Diabetes medications and body weight","volume":"8","author":"Mitri","year":"2009","journal-title":"Expert Opin Drug Saf"},{"key":"10.4158\/EP12325.OR_bb0090","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00008571-199712000-00006","article-title":"D2 dopamine receptor gene (DRD2) Taq1 A polymorphism: Reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele","volume":"7","author":"Thompson","year":"1997","journal-title":"Pharmacogenetics"},{"key":"10.4158\/EP12325.OR_bb0095","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S0140-6736(00)03643-6","article-title":"Brain dopamine and obesity","volume":"357","author":"Wang","year":"2001","journal-title":"Lancet"},{"key":"10.4158\/EP12325.OR_bb0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.nut.2008.07.012","article-title":"D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes","volume":"25","author":"Barnard","year":"2009","journal-title":"Nutrition"},{"key":"10.4158\/EP12325.OR_bb0105","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2165\/11596300-000000000-00000","article-title":"Atypical antipsychotic-induced weight gain: insights into mechanisms of action","volume":"25","author":"Roerig","year":"2011","journal-title":"CNS Drugs"},{"key":"10.4158\/EP12325.OR_bb0110","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2337\/dc11-2250","article-title":"Relationship of dopamine type 2 receptor binding potential with fasting neuroendocrine hormones and insulin sensitivity in human obesity","volume":"35","author":"Dunn","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12325.OR_bb0115","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.2337\/db06-0376","article-title":"Attenuation of insulin-evoked responses in brain networks controlling appetite and reward in insulin resistance: the cerebral basis for impaired control of food intake in metabolic syndrome?","volume":"55","author":"Anthony","year":"2006","journal-title":"Diabetes"},{"key":"10.4158\/EP12325.OR_bb0120","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/0026-0495(91)90057-4","article-title":"Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance, and impaired glucose tolerance in the Syrian hamster, Mesocricetus auratus","volume":"40","author":"Cincotta","year":"1991","journal-title":"Metabolism"},{"key":"10.4158\/EP12325.OR_bb0125","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/BF01930467","article-title":"Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics","volume":"48","author":"Meier","year":"1992","journal-title":"Experientia"},{"key":"10.4158\/EP12325.OR_bb0130","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/07420529309059707","article-title":"Circadian neuroendocrine role in age-related changes in body fat stores and insulin sensitivity of the male Sprague-Dawley rat","volume":"10","author":"Cincotta","year":"1993","journal-title":"Chronobiol Int"},{"key":"10.4158\/EP12325.OR_bb0135","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0024-3205(97)00599-7","article-title":"Bromocriptine\/SKF38393 treatment ameliorates obesity and associated metabolic dysfunctions in obese (ob\/ob) mice","volume":"61","author":"Cincotta","year":"1997","journal-title":"Life Sci"},{"key":"10.4158\/EP12325.OR_bb0140","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2337\/diacare.23.8.1154","article-title":"Bromocriptine: a novel approach to the treatment of type 2 diabetes","volume":"23","author":"Pijl","year":"2000","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12325.OR_bb0145","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/0024-3205(89)90066-0","article-title":"Reductions of body fat stores and total plasma cholesterol and triglyceride concentrations in several species by bromocriptine treatment","volume":"45","author":"Cincotta","year":"1989","journal-title":"Life Sci"},{"key":"10.4158\/EP12325.OR_bb0150","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000054415","article-title":"Intracerebroventricular administration of bromocriptine ameliorates the insulin-resistant\/glucose-intolerant state in hamsters","volume":"69","author":"Luo","year":"1999","journal-title":"Neuroendocrinology"},{"key":"10.4158\/EP12325.OR_bb0155","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1097\/00001756-199711100-00016","article-title":"Dopaminergic neurotoxin administration to the area of the suprachiasmatic nuclei induces insulin resistance","volume":"8","author":"Luo","year":"1997","journal-title":"Neuroreport"},{"key":"10.4158\/EP12325.OR_bb0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000054344","article-title":"Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine metabolite levels in the ventromedial hypothalamus of Syrian hamsters","volume":"68","author":"Luo","year":"1998","journal-title":"Neuroendocrinol"},{"key":"10.4158\/EP12325.OR_bb0165","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1517\/13543784.8.10.1683","article-title":"Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes","volume":"8","author":"Cincotta","year":"1999","journal-title":"Expert Opin Investig Drugs"},{"key":"10.4158\/EP12325.OR_bb0170","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/BF00404020","article-title":"The dawn phenomenon in type 1 (insulin-dependent) diabetes mellitus: magnitude, frequency, variability, and dependency on glucose counter-regulation and insulin sensitivity","volume":"34","author":"Boden","year":"1991","journal-title":"Diabetologia"},{"key":"10.4158\/EP12325.OR_bb0175","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nm1201","article-title":"Hypothalamic sensing of circulating fatty acids is required for glucose homeostasis","volume":"11","author":"Lam","year":"2005","journal-title":"Nat Med"},{"key":"10.4158\/EP12325.OR_bb0180","first-page":"464","article-title":"Circadian rhythms regulate the expression of the thrifty genotype\/phenotype","volume":"4","author":"Meier","year":"1996","journal-title":"Diabetes Rev"},{"key":"10.4158\/EP12325.OR_bb0185","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0006-8993(86)90530-5","article-title":"Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats","volume":"369","author":"Shimazu","year":"1986","journal-title":"Brain Res"},{"key":"10.4158\/EP12325.OR_bb0190","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/308065a0","article-title":"Relationships between brain noradrenergic activity and blood glucose","volume":"308","author":"Smythe","year":"1984","journal-title":"Nature"},{"key":"10.4158\/EP12325.OR_bb0195","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: a sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes","volume":"34","author":"DeFronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12325.OR_bb0200","series-title":"Frontiers in Animal Diabetes Research","first-page":"271","article-title":"Hypothalamic role in Insulin Resistance and insulin Resistance Syndrome","author":"Cincotta","year":"2002"},{"key":"10.4158\/EP12325.OR_bb0205","doi-asserted-by":"crossref","first-page":"007","DOI":"10.4172\/2155-6156.S2-007","article-title":"Weighted effects of bromocriptine treatment on glucose homeostasis during hyperglycemic versus euglycemic clamp conditions in insulin resistant hamsters: bromocriptine as a unique postprandial insulin sensitizer","volume":"S2","author":"Ezrokhi","year":"2012","journal-title":"J Diabetes Metab"},{"key":"10.4158\/EP12325.OR_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11906-011-0243-6","article-title":"Epinephrine and the metabolic syndrome","volume":"14","author":"Ziegler","year":"2012","journal-title":"Curr Hypertens Rep"},{"key":"10.4158\/EP12325.OR_bb0215","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2337\/dc09-2009","article-title":"Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes","volume":"33","author":"Gaziano","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/EP12325.OR_bb0220","first-page":"931","article-title":"Effect of bromocriptine-QR on glycemic control in subjects with type 2 diabetes having uncontrolled hyperglycemia on one or two oral anti-diabetes agents","volume":"18","author":"Vinik","year":"2012","journal-title":"J Clin Endo Metab"},{"key":"10.4158\/EP12325.OR_bb0225","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1517\/14656560903501544","article-title":"Bromocriptine-unique formulation of a dopamine agonist for the treatment of type 2 diabetes","volume":"11","author":"Scranton","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.4158\/EP12325.OR_bb0230","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1499-2671(09)33133-0","article-title":"Quick release bromocriptine (Cycloset\u00ae) a novel treatment for type 2 diabetes also demonstrates improvements in blood pressure","volume":"33","author":"Scranton","year":"2009","journal-title":"Can J Diabetes"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041239X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2041239X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/WV5737QP11823NR2.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:55:13Z","timestamp":1761515713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2041239X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["S1530891X2041239X"],"URL":"https:\/\/doi.org\/10.4158\/ep12325.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Bromocriptine-Qr in the Management of Type 2 Diabetes Expert Panel Recommendations","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP12325.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}